Inflammation as a tumor promoter in cancer induction

Seminars in Cancer Biology

Volumn 14, Issue 6, 2004, Pages 433-439

  Philip, Mary ^a   Rowley, Donald A ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Apoptosis; Carcinogenesis; FasL; IL 6; Infections; Interferons; Mutations; NF B; p53; T cells; TNF

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CASPASE; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P53; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR PROMOTER;

APOPTOSIS; CANCER STAGING; CARCINOGENESIS; CELL SURVIVAL; CHRONIC INFLAMMATION; DISEASE COURSE; DNA REPAIR; DRUG EFFECT; HUMAN; INFLAMMATION; NONHUMAN; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE;

EID: 5444256371     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2004.06.006     Document Type: Article

References (81)

1. Virchow R. Reizung und Reizbarkeit. Arch. Pathol. Anat. Klin. Med. 14:1858;l-63
2. Virchow R. Aetiologie der neoplastischen Geschwülste/Pathogenie der neoplastischen Geschwülste. In: Die Krankhaften Geschwülste. Berlin: Verlag von August Hirschwald; 1863, p. 57-101.
3. Fehleisen F. Über die Züchtung der Erysipel-Kokken auf künstlichen Nährböden und die Übertragbarkeit auf den Menschen. Deutsche Med Wschr. 8:1882;553-554
4. Bruns P. Die Heilwirkung des Erysipels auf Geschwülste. Beitr Klin Chir. 3:1887/1888;443-466
5. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105:1893;487-511
6. Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116:1976;180-183
7. Campbell JA. Influenza virus and incidence of primary lung tumors in mice. Lancet 1940;II:487.
8. Steiner PE. The effect of influenza virus (type A) on the incidence of lung tumors in mice. Cancer Res 1950;10.
9. Schreiber H., Nettesheim P., Lijinsky W., Richter C.B., Walburg H.E. Jr. Induction of lung cancer in germfree, specific-pathogen-free, and infected rats by N-nitrosoheptamethyleneimine: enhancement by respiratory infection. J. Natl. Cancer Inst. 49:1972;1107-1114
10. Schreiber H, Rowley DA. Inflammation and cancer. In: Gallin JI, Snyderman R, editors. Inflammation: basic principles and clinical correlates, third ed. Philadelphia: Lippincott Williams & Wilkins; 1999, p. 1117-29.
11. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 357:2001;539-545
12. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 420:2002;860-867
13. Kolstad P., Klem V. Long-term followup of 1121 cases of carcinoma in situ. Obstet. Gynecol. 48:1976;125-129
14. Yamagiva Kal K. Experimental study of the pathogenesis of cancer. J. Cancer Res. 3:1918;1-21
15. Rous P., Beard J.W. The progression to carcinoma of virus-induced rabbit papillomas (Shope). J. Exp. Med. 185(4):1997;695-705. Feb. 17, 1935;62:523-8
16. Rous P., Kidd J.G. Conditional neoplasms and subthreshold neoplastic states. A study of the tar tumors of rabbits. J. Exp. Med. 185(4):1997;695-705. Feb. 17, 1941;73:365-90
17. Berenblum I. The mechanism of carcinogenesis: a study of the significance of cocarcinogenic action. Cancer Res. 1:1941;807-814
18. Foulds L. The experimental study of tumor progression. A review. Cancer Res. 14:1954;327-339
19. Foulds L. Natural history of cancer. J. Chron. Dis. 8:1958;1-33
20. Hecker E. Phorbol esters from croton oil. Chemical nature and biological activities. Naturwissenschaften. 54:1967;282-284
21. Klein G., Klein E. Evolution of tumours and the impact of molecular oncology. Nature. 315:1985;190-195
22. Fearnhead N.S., Wilding J.L., Bodmer W.F. Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis. Br. Med. Bull. 64:2002;27-43
23. Loeb L.A., Loeb K.R., Anderson J.P. Multiple mutations and cancer. Proc. Natl. Acad. Sci. USA. 100:2003;776-781
24. Old L.J. Tumor necrosis factor. Sci. Am. 258:1988;59-60. 9-75
25. Suganuma M., Okabe S., Marino M.W., Sakai A., Sueoka E., Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res. 59:1999;4516-4518
26. Moore R.J., Owens D.M., Stamp G., Arnott C., Burke F., East N., et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 5:1999;828-831
27. Lin A., Karin M. NF-kappaB in cancer: a marked target. Semin. Cancer Biol. 13:2003;107-114
28. Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 114:2003;181-190
29. Barnhart B.C., Peter M.E. The TNF receptor 1: a split personality complex. Cell. 114:2003;148-150
30. Klein G. Cancer, apoptosis, and non-immune surveillance. Cell Death Differ. 11:2004;13-17
31. Van Der Woude C.J., Kleibeuker J.H., Jansen P.L., Moshage H. Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract. Apoptosis. 9:2004;123-130
32. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., et al. Suppression of intestinal polyposis in Ape delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809
33. Young M.R., Yang H.S., Colburn N.H. Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4. Trends Mol. Med. 9:2003;36-41
34. Maeda S., Karin M. Oncogene at last - c-Jun promotes liver cancer in mice. Cancer Cell. 3:2003;102-104
35. Eferl R., Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer. 3:2003;859-868
36. Lee J.K., Sayers T.J., Back T.C., Wigginton J.M., Wiltrout R.H. Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis. 8:2003;151-160
37. Desbarats J., Newell M.K. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med. 6:2000;920-923
38. Nakamoto Y., Kaneko S., Fan H., Momoi T., Tsutsui H., Nakanishi K. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J. Exp. Med. 178(3):1993;933-940. Sept. 1, 2002;196:1105-11
39. Nakamoto Y., Guidotti L.G., Kuhlen C.V., Fowler P., Chisari F.V. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 178(3):1993;933-940. Sept. 1, 1998:188:341-50
40. Leder A., Kuo A., Cardiff R.D., Sinn E., Leder P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA. 87:1990;9178-9982
41. Siegel C.T., Schreiber K., Meredith S.C., Beck-Engeser G.B., Lancki D.W., Lazarski C.A., et al. Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutation region of an inherited oncoprotein. J. Exp. Med. 185(4):2000;695-705. 1997, Feb. 17
42. Daniel D., Meyer-Morse N., Bergsland E.K., Dehne K., Coussens L.M., Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ T cells. J. Exp. Med. 178(3):1993;933-940. Sept. 1, 2003;197:1017-28
43. Girardi M., Glusac E., Filler R.B., Roberts S.J., Propperova I., Lewis J., et al. The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J. Exp. Med. 178(3):2003;933-940. Sept. 1, 2003;198:474-55
44. Hudson J.D., Shoaibi M.A., Maestro R., Carnero A., Hannon G.J., Beach D.H. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 185(4):1997;695-705. Feb. 17, 1999;190:1375-82
45. Cordon-Cardo C., Prives C. At the crossroads of inflammation and tumorigenesis. J. Exp. Med. 185(4):1999;697-705. Feb. 17, 1999;190:1367-70
46. Potter M. Neoplastic development in plasma cells. Immunol. Rev. 194:2003;177-195
47. Merwin R.M., Algire G.H. Induction of plasma-cell neoplasms and fibrosarcomas in B ALB/c mice carrying diffusion chambers. Proc. Soc. Exp. Biol. Med. 101:1959;437-439
48. Merwin R.M., Redmon L.W. Induction of Plasma cell tumors and sarcomas in mice by diffusion chambers placed in the peritoneal cavity. J. Natl. Cancer Inst. 31:1963;997-1017
49. Anderson P.N., Potter M. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature. 222:1969;994-995
50. Athanassiades T.J., Speirs R.S. Formation of antigen-induced granulomas containing plasma cells: a light and electron microscopic study. J. Reticuloendothel. Soc. 5:1968;485-497
51. Athanassiades T.J., Speirs R.S. Granuloma induction in the peritoneal cavity. A model for the study of inflammation and plasmacytopoiesis in nonlymphatic organs. J. Reticuloendothel. Soc. 11:1972;60-76
52. Takakura K., Mason W.B., Hollander V.P. Studies on the pathogenesis of plasma cell tumors. I. Effect of cortisol on development of plasma cell tumors. Cancer Res. 26:1966;596-599
53. Potter M., Wax J., Jones G.M. Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain. Blood. 90:1997;260-269
54. Lattanzio G., Libert C., Aquilina M., Cappelletti M., Ciliberto G., Musiani P., et al. Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am. J. Pathol. 151:1997;689-696
55. Suematsu S., Matsuda T., Aozasa K., Akira S., Nakano N., Ohno S., et al. IgGl plasmacytosis in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA. 86:1989;7547-7551
56. Suematsu S., Matsusaka T., Matsuda T., Ohno S., Miyazaki J., Yamamura K., et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. USA. 89:1992;232-235
57. Burger R., Guenther A., Bakker F., Schmalzing M., Bernand S., Baum W., et al. Gpl30 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol. J. 2:2001;42-53
58. Nishida K., Tamura A., Nakazawa N., Ueda Y., Abe T., Matsuda F., et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood. 90:1997;526-534
59. Skopelitou A., Hadjiyannakis M., Tsenga A., Theocharis S., Alexopoulou V., Kittas C., et al. Expression of C-myc p62 oncoprotein in multiple myeloma: an immunohistochemical study of 180 cases. Anticancer Res. 13:1993;1091-1095
60. Nobuyoshi M., Kawano M., Tanaka H., Ishikawa H., Tanabe O., Iwato K., et al. Increased expression of the c-myc gene may be related to the aggressive transformation of human myeloma cells. Br. J. Haematol. 77:1991;523-528
61. Hoffman B., Amanullah A., Shafarenko M., Liebermann D.A. The proto- oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene. 21:2002;3414-34121
62. Amanullah A., Liebermann D.A., Hoffman B. p53-independent apoptosis associated with c-Myc-mediated block in myeloid cell differentiation. Oncogene. 19:2000;2967-2977
63. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gpl30/Jak/STAT pathway. Biochem. J. 334:1998;297-314
64. Ogata A., Chauhan D., Teoh G., Treon S.P., Urashima M., Schlossman R.L., et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J. Immunol. 159:1997;2212-2221
65. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10:1999;105-115
66. Moore P.S., Boshoff C., Weiss R.A., Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 274:1996;1739-1744
67. Cannon J.S., Nicholas J., Orenstein J.M., Mann R.B., Murray P.G., Browning P.J., et al. Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J. Infect. Dis. 180:1999;824-828
68. Aoki Y., Jaffe E.S., Chang Y., Jones K., Teruya-Feldstein J., Moore P.S., et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 93:1999;4034-4043
69. Rettig M.B., Ma H.J., Vescio R.A., Pold M., Schiller G., Belson D., et al. Kaposi's sarcoma-assoicated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science. 276:1997;1851
70. Kastrinakis N.G., Gorgoulis V.G., Foukas P.G., Dimopoulos M.A., Kittas C. Molecular aspects of multiple myeloma. Ann. Oncol. 11:2000;1217-1228
71. Takaoka A., Hayakawa S., Yanai H., Stoiber D., Negishi H., Kikuchi H., et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 424:2003;516-523
72. Townsend P.A., Scarabelli T.M., Davidson S.M., Knight R.A., Latchman D.S., Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J. Biol. Chem. 279:2004;5811-5820
73. Nozawa H., Oda E., Nakao K., Ishihara M., Ueda S., Yokochi T., et al. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev. 13:1999;1240-1245
74. Ehrlich P. Uber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd. 5:1909;273-290
75. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:2001;1107-1111
76. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA. 95:1998;7556-7561
77. Qin Z., Blankenstein T. A cancer immunosurveillance controversy. Nat. Immunol. 5:2004;3-4. author reply 5
78. Thomas L. In: Lawrence HS, editor. Discussion of cellular and humoral aspects of the hypersensitive states. New York: Hoeber-Harper; 1959, p. 529-32.
79. Burnet F.M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13:1970;1-27. 1970;13:l-27
80. Klein G. Immunological surveillance against neoplasia. Harvey Lect. 69:1975;71-102
81. Schreiber H, Tumor immunology, chapter 48. In: Paul WE, editor. Fundamental Immunology. Fifth edition. Philadelphia: Lippincott-Williams & Wilkins; 2003. p. 1557-92.